C-EQFTPrellis Biologics
AI antibody discovery, bioprinted organoids, immune diversity
discoverydiscoveringbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EQFT
C-EQFTC-EQFTAI antibody discovery, bioprinted organoids, immune diversity
0-100 chain-logic scale · 15 dimensions · scored on public evidence
We explore how to move IVIG from donor scarcity to on‑demand manufacturing with tissue‑engineered bioreactors, and why that shift could lower costs, expand access, and improve consistency. We dig into polyclonal advantages, regulatory guardrails, scaling plans, and what success would mean for complex biologics beyond antibodies. • Defining a bioreactor that recreates human tissue niches • Why polyclonal IVIG remains essential across 100+ conditions • Limits of donor‑dependent plasma supply and regional variability • Complex therapeutics as a new manufacturing category • Cost targets of 10–100x reduction and CapEx shrink • Coffee‑cup reactors and near‑term validation milestones • Quality metrics including pathogen panels and glycosylation • Donor variability, blending strategies, and future immortalization • Clinical impact of moving from rationing to earlier use • Funding update and industry partnerships Please listen to the disclaimer at the end of this podcast. Show notes: https:
AI is reshaping drug discovery—but it isn’t inventing medicines on its own yet. On the TechSurge podcast, Prellis Biologics CEO Mike Nohaile breaks down what AI does well, what it can’t, and why human immune biology still sets the rules. He also explains how bioprinted lymph node organoids (EXIS) can model real human immune responses and speed up the discovery of new, better medicines. Subscribe for more TechSurge shorts. #TechSurge #MikeNohaile #PrellisBiologics #DrugDiscovery #AI #Biotech #3DBioprinting #ImmuneSystem #LymphNodeOrganoids #Shorts
Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do? In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis’ unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits. LINKS Explore Prellis Biologics https://prellisbi
On our latest TechSurge podcast, Prellis Biologics CEO Mike Nohaile explains why AI-created medicines have been overhyped and why - in reality - they are still decades away. Dive in: https://youtu.be/Epjtq527EEc?si=ActwP5vm-O_RMNqC
Hosted by venture investment firm Celesta Capital, TechSurge is an annual Deep Tech conference fostering dialogue at the intersection of technology advancement, entrepreneurship, and the investment landscape. Learn more at techsurgesummit.com. This panel explores the booming area of bioconvergence, which sits at the intersection of high tech and biotech. Moderator: Lareina Yee, Senior Partner, McKinsey & Co. Speakers: James Rothman, PhD, Nobel Prize Winner, Professor, Yale University Melanie Matheu, PhD, Founder, Prellis Biologics Shaun Holt, CEO, Alveo
Using AI for organ transplant, faster drug discovery, and safer autonomous cars. Shereen Bhan speaks to Nicholas Brathwaite & Sriram Viswanathan, Founding Managing Partners at Celesta Capital along with Marc Bolitho of Recogni & Mike Nohaile of Prellis Biologics. #artificialintelligence #ai #generativeai #drone #cnbctv18 #stockmarketupdates #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday 🔴CNBC TV18 LIVE TV: https://youtube.com/live/P857H4ej-MQ SUBSCRIBE to our Channel: https://bit.ly/3nvEcxf --------------------------------------------------------------------------------------------------------------------- 👑 Check Out Top CNBC TV18 Playlist Videos: 🔹CNBC TV18 Classic Interviews: https://www.youtube.com/playlist?list=PLjq9mRS1PfGDmfXVg7XEQngsCY9RoS-fv 🔹CNBC TV18 Digital: https://www.youtube.com/playlist?list=PLjq9mRS1PfGDCcaVZ_82M9vhLo9lGJYzo 🔹CNBC TV18 Weekend Special: https://www.youtube.com/playlist?list=PLjq9mRS
Using AI for organ transplant, faster drug discovery, and safer autonomous cars. Shereen Bhan speaks to Nicholas Brathwaite & Sriram Viswanathan, Founding Managing Partners at Celesta Capital along with Marc Bolitho of Recogni & Mike Nohaile of Prellis Biologics. #artificialintelligence #ai #generativeai #healthcare #automobile #cnbctv18 #stockmarketupdates #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday 🔴CNBC TV18 LIVE TV: https://youtube.com/live/P857H4ej-MQ SUBSCRIBE to our Channel: https://bit.ly/3nvEcxf --------------------------------------------------------------------------------------------------------------------- 👑 Check Out Top CNBC TV18 Playlist Videos: 🔹CNBC TV18 Classic Interviews: https://www.youtube.com/playlist?list=PLjq9mRS1PfGDmfXVg7XEQngsCY9RoS-fv 🔹CNBC TV18 Digital: https://www.youtube.com/playlist?list=PLjq9mRS1PfGDCcaVZ_82M9vhLo9lGJYzo 🔹CNBC TV18 Weekend Special: https://www.youtube.com/playlis
Using AI for organ transplant, faster drug discovery, and safer autonomous cars. Shereen Bhan speaks to Nicholas Brathwaite & Sriram Viswanathan, Founding Managing Partners at Celesta Capital along with Marc Bolitho of Recogni & Mike Nohaile of Prellis Biologics. #ai #artificialintelligence #cnbctv18 #stockmarketupdates #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday About CNBC-TV18: India's leading business news channel, CNBC-TV18 offers the most comprehensive coverage of businesses, the economy and the financial markets. Catch all your favourite shows, exclusive videos, big-ticket interviews and more here. You can also connect with CNBC-TV18 News Online Catch the latest news: https://bit.ly/2YbpXBM Follow CNBC-TV18 round the clock: https://www.cnbctv18.com/live-tv/ Stay updated with all the market action in real time: https://www.cnbctv18.com/market-live/ You can also stay updated with all the latest news on-the-go with CNBC-TV18 Minis: https://www.
Prellis Biologics , a company developing the tools to create 3D printed organs, announced a $14.5 million Series B round on Wednesday. Prellis has spent years developing tissue engineering capacity, but has focused recently on developing one type of structure in particular. Up until this point, Prellis has focused on 3D printing vascular scaffolds that would allow companies to grow healthy and oxygenated human organs (or miniature versions, called organoids) for drug testing, and eventually transplant. But the company has recently debuted a new product, called EXIS (short for Externalized Immune System): a lab-grown version of a human lymph node. Lymph nodes are critical parts of the human immune system – they store certain immune cells, and help the body manufacture immune responses. Ideally, those lymph node organoids would aid in drug development by mimicking how a person’s immune system might respond to new treatment. And, perhaps, help create some new drugs along
In Episode 18, Season 3 of the Amplifying Scientific Innovation Video Podcast, Dr. Sophia Ononye-Onyia, Founder and CEO of The Sophia Consulting Firm, interviewed Dr. Melanie Matheu, Founder and CEO of Prellis Biologics. Here, Dr. Matheu shares anecdotes of her scientific leadership journey, industry outlook and her company’s pioneering focus on developing holographic laser projection printing and applying this method for the development of human tissues and organs. For full transcript, please visit: https://sophiaconsultingfirm.com/blogs-%2B-articles/f/amplifying-scientific-innovationdr-matheu-ceo-prellis-biologics
How can current loosening of red tape around COVID-19 interventions be extended to ease the way for high-impact science? Robin Hanson, George Mason University Jim O'Neill, SENS Research Foundation John Lewis, Aegis Biodefence Melanie Matheu, Prellis Biologics Zoom Session Transcriptions: https://otter.ai/s/ZcOgQYMlRyWl-8tMuvisXw HiveMind | Long-term Futures in Times of Acute Crisis If a catastrophe is an event which causes the loss of most expected value, a eucatastrophe is an event which causes there to be much more expected value after the event than before. Currently, there may be a few unique opportunities to steer the COVID-19 crisis away from catastrophe toward eucatastrophe. Some demand urgency given the speed with which the crisis is changing and the likely short time-window in which it will be possible to push for those ideas. The earlier we start exploring options, the better. Foresight Hivemind is a three-weeks global online workshop to develop promising opportuniti
Prellis Biologics is making human anti-SARS-CoV2 antibodies for use against COVID-19 using bioprinted, human mini lymph nodes. In 2017, the printed lymph nodes produced human antibodies for passive immunity against Zika virus. Now, Prellis is doing the same for the coronavirus. The mini lymph node system produces antibodies in a little over a month. The lymph nodes develop from immune cells within a week, and the antibodies produced from these lymph nodes are ready for screening after another month. Six weeks after the process begins, the antibodies are sequenced for scale-up and additional trials, which can begin in as few as 10 weeks. This faster turnaround time represents a more rapid method to generate antibodies that have potential for protection against COVID-19. Transcript: 00:00 I'm Julie Wolf of IndieBio and I'm speaking with Melanie Matheu, PhD, of Prellis Biologics today about how her system allows the generation of human monoclonal antibodies outside of the human body. 00
Rapid Production of Human Antibodies Using an Externalized Human Immune System: How does your body make good antibodies, and how can we hack what we know about the human immune system to protect ourselves from pathogens? Melanie Matheu, Prellis Biologics. At Prellis Biologics we are dedicated to ending the global human organ shortage by building real medical solutions that leverage the power of human cells to re-create tissues and organs for transplantation. I am a research scientist turned entrepreneur with cross-disciplinary experience in Immunology, Chemistry, Biophysics, Molecular Biology, and Protein Engineering. With a specialty (15+ years) in 2-photon imaging of immune responses. In my career I have filed 7 patents, worked on 2 immunotherapeutics, covered biotechnology companies for investors for over 20 years, and served as the youngest member on the SAB of a companion animal medicine company. My first patent work was at the age of 19 in the field of synthetic organic chemistr
3D Printed Organs? Sounds like SciFi, but in this Female Founder Spotlight, Melanie Matheu talks about her quest to make it a reality as the CEO and Co-Founder of Prellis Biologics. "Building life with light," and leading the human tissue engineering revolution...►Subscribe to SOSV: https://bit.ly/2AXgcLk ► Learn the language of Venture Capital with VC Lingo at: https://goo.gl/vHB7kP ► More insights into top Venture Capital firms from the VCs that run them via 42 Questions: https://bit.ly/2lIfZYs To learn more about SOSV, check out http://sosv.com More about Prellis Biologics at: https://www.prellisbio.com WHO WE ARE, WHAT WE DO, WHY WE DO IT SOSV is a multi-stage venture capital investor. We run multiple world-class vertical accelerator programs, and provide seed, venture and growth stage follow-on investment into superstar companies. Our unique full-stack model has delivered a net IRR over the last 20 years that puts us in the top 10% of all venture funds worldwide. SOSV provides
What if you could build life with light? CEO and Founder Melanie Matheu and her team at Prellis Biologics have created a machine that can build full organ systems by projecting high resolution laser light—even forming the acute capillaries that breathe air through our bodies. Watch her TEDMED 2018 talk to learn how Prellis Biologics is using light to build a path to restore life.
Implantable 3D-printed organs could be coming sooner than you think At MBC Biolabs, an incubator for new biotechnology companies in the Dogpatch neighborhood of San Francisco, a team of scientists and interns working for small business Prellis Biologics has just taken a big step in the development of viable organs printed in 3D for humans . The company, which was founded in 2016 by scientists Melanie Matheu and Noelle Mullin, bet its future (and a small investment of $ 3 million) on a new technology to manufacture capillaries, the blood vessels of a cell thick that are the ways that oxygen and nutrients move to nourish the tissues in the body. Without functional capillary structures, it is impossible to make organs, according to Matheu. They are the most vital piece of the puzzle in the search for viable hearts, livers, kidneys and lungs, he said. "The microvasculature is the fundamental architectural unit that supports advanced multicellular life and, therefore, represents a crucia
Melanie is the CEO and Founder of Prellis Biologics, growing human organs as an engineering company. https://www.prellisbio.com/ ****** Simulation is rebirthing the public intellectual and inspiring YOU to build the future through our multidisciplinary daily show and live events series. ****** We are fan-funded thanks to the Patronage of people who find our content useful. Help us become sustainable and expand our content. https://www.patreon.com/simulationseries Follow us on Twitter: https://twitter.com/simulationshow Follow us on Facebook: https://www.facebook.com/simulationseries Follow us on Instagram: https://www.instagram.com/simulationseries/ ****** Here's our full list of thought-provoking questions: www.simulationseries.com/the-list Reach out to us! We'd love to hear from you and we're always looking for people to join our team, please email: [email protected]
Please watch: "James Rickards - LIVE on BIDS: The New Great Depression, Currency Wars" https://www.youtube.com/watch?v=FkELlnM14gg --~-- Like something in a movie, Melanie Matheu peered into a microscope and saw the future. A time when lasers print organs. This week Sandra and I feature Prellis Biologics. Our guests are a powerhouse duo, Co-Founders CEO Melanie Matheu, Ph.D. and Noelle Mullin, Ph.D., CSO. Prellis Biologics is another company from the IndieBio accelerator which is tied to SOSV’s efforts to invest in biotech. By their own estimate, transplantable kidneys (or whichever organ they produce first—for this article we’ll use kidneys) will be available in 5 to 8 years. #tinydinosaurs #alecbaldwin #podcast #birthdaypodcast #BUBBL #3dPrinting #printingorgans
Tech brought to life by three keynotes at Slush 2017. Here Melanie Matheu, Co-founder of Prellis Biologics, gives his keynote on how biology benefits from technological discoveries. -- In 2017, Slush brought together 20,000 attendees, including 2,600 startups, 1,500 investors and 600 journalists from over 130 countries. The cold and dark Helsinki welcomed these tech-heads to a week long celebration, including Slush Music, new Slush Y verticals, and hundreds of side-events and activities around the city. Slush 2018 takes place on 4.–5.12.2018 Slush 2017 in pictures: https://www.flickr.com/photos/slushmedia/albums Website: http://www.slush.org Facebook: http://www.facebook.com/slushHQ Twitter: http://www.twitter.com/slushHQ Instagram: http://instagram.com/SlushHQ Linkedin: http://www.linkedin.com/company/slush Slush Music: http://music.slush.org Slush Tokyo: http://tokyo.slush.org Slush Shanghai: http://shanghai.slush.org Slush Singapore: http://singapore.slush.org Intro videos by:
3D Dentistry. Journey of the Rise of Digital Dentistry A life science talk on 3D/Bio Printing Dentistry by the 3DHeals Dental Ambassador Dr. Nabeel Cajee hosted by the German American Business Association and given at Squire Boggs Patton in Downtown San Francisco, October 2017. Other Speakers that evening included: Dr. Melanie Matheu, CEO Prellis Biologics Dr. Mayasari Lim , CEO, SE3D Tom Anderton, Intellectual Property Attorney, Squire, Patton, Boggs www.drcajee.co
Prellis Biologics: Revolutionizing Antibody Discovery & Drug Development With Holographic Printing Technology | Celesta Capital granted update happens via the Termly Consent Mode template inside GTM. Do not add an update listener to this head. ========================================================= --> × United States of America Aaland Islands Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, … y meets deep tech—but we were left with the burning question: Was this a viable application of their revolutionary innovation? We gravitated to evaluating Prellis’ technology as a platform for innovation, considering which of its budding applications could have the greatest impact on public health and best position it for success. Prellis lymph node organoid and core EXIS platform applications. Constructing a Human Immune System We learned that Prellis could construct lymph n
Life from Light - Prellis Biologics | TomorrowScale Life from Light - Prellis Biologics | TomorrowScale Episodes About TomorrowScaleVC Connect TomorrowScale Scientists, engineers, and entrepreneurs building the future. Stories from the cutting edge of science and medicine. Share Life from Light - Prellis Biologics On this episode, we’ll meet Melanie Matheu, Ph.D., a scientist turning light into life. Her company, Prellis Biologics, has developed what may be a defining technology for the bioprinting industry: A method to print biology on the cellular level. They’re shipping printed vasculature
Prellis Biologics’ Melanie Mat… - The Times Tech Podcast - Apple Podcasts Search Home New Top Charts Search October 18, 2019 42 min Prellis Biologics’ Melanie Matheu: “Lab-grown kidneys" The Times Tech Podcast Play The Sunday Times’ tech correspondent brings on Merlanie Matheu, founder of Prellis Biologics, to talk about 3D-printing organs (2:15), cellular scaffolding (3:35), implanting lab-grown tumours in rats (5:15), why this is a big deal (6:35), solving the kidney (7:55), the magic of 3D printing (12:00), how she got into tissue engineering (13:45), filing a patent before knowing she coul
Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BeBeez Contacts Wednesday, 10 June 2026 English Newsletter . Home RISK CAPITAL Private capital in the world Private capital in Europe Private capital in Asia Pacific Private capital in North America Private capital in the rest of the world Real Estate in the world Real estate in Europe Real Estate in Asia Pacific Real Estate in North America Real Estate in the rest of the world CREDIT & DEBT ANALYSIS  … d members: Lei Meng, Senior Therapeutics Analyst of Avidity Partners, and Nobel Prize winner James Rothman, PhD the Sterling Professor of Cell Biology at Yale University. “The multi-billion-dollar antibody therapeutics market is held back by slow discovery. Until now, data on human immune response to guide development of effective drugs or vaccines has only been available through large, expensive clinical trials,” said Michael Marks, Prellis Bio Board Chairman and Founding Ma
Why AI Isn't Ready to Make Med… - TechSurge: Deep Tech Podcast - Apple Podcasts Search Home New Top Charts Search March 13, 2025 42 min Why AI Isn't Ready to Make Medicines TechSurge: Deep Tech Podcast Play Many in venture capital and biopharma are anointing artificial intelligence the savior of drug discovery—but what can AI actually do? In this eye-opening episode, Michael Marks sits down with Mike Nohaile, CEO of Prellis Biologics, to explore the hype versus reality in AI-enabled drug discovery. Mike details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win fo … protein structures https://deepmind.google/alphafold Read about the 2024 Nobel Prize in Chemistry https://www.nobelprize.org/prizes/chemistry/2024/press-release/ (00:00) - The Reality of AI in Drug Discovery (03:05) - The Need for Better Medicines (06:05) - Evolution of Pharmaceutical Therapies (08:55) - Challenges in Protein Drug Discovery (12:13) - AI's Role in Protein Design (14:46) - Limitations of AI in Drug Development (17:58) - Understanding Protein Struct
Amplifying Scientific Innovation:Dr Matheu, CEO Prellis Biologics Home Advisory Podcast Apprenticeship Insights Bookshop Toolkit Leadership Home Advisory Podcast Apprenticeship Insights Bookshop Toolkit Leadership More Home Advisory Podcast Apprenticeship Insights Bookshop Toolkit Leadership Home Advisory Podcast Apprenticeship Insights Bookshop Toolkit Leadership Success is not final, failure is not fatal: it is the courage to continue that counts. Winston Churchill Insights Subscribe Get 10% off your first purchase when you sign up for our newsletter! Email Sign up Amplifying Scientific Inno
Organ Printing with Melanie Matheu of Prellis Biologics - Near Frontier | Podcast on Spotify
Prellis Biologics’ Melanie Matheu: “Lab-grown kidneys" - The Times Tech Podcast | Acast Follow Share Play The Times Tech Podcast Prellis Biologics’ Melanie Matheu: “Lab-grown kidneys" Season 1 • Friday, October 18, 2019 The Sunday Times’ tech correspondent brings on Merlanie Matheu, founder of Prellis Biologics, to talk about 3D-printing organs (2:15), cellular scaffolding (3:35), implanting lab-grown tumours in rats (5:15), why this is a big deal (6:35), solving the kidney (7:55), the magic of 3D printing (12:00), how she got into tissue engineering (13:45), filing a patent before k
Episode 10 - Melanie Matheu ‑ TeddyTalk Podcast ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 14 septembre 2018 42 min Episode 10 - Melanie Matheu TeddyTalk Podcast Lire This week I spoke with Dr. Melanie Matheu, the Founder and CEO of Prellis Biologics. Dr. Matheu has a background in Immunology, Chemistry, Physiology, & Biophysics…and what have you done lately? I first met Melanie when we were virtually introduced by a mutual acquaintance. The intro email said something like: “Teddy - please meet Mel who is one of the fastest rising CEOs in SF (and) who might keep
Organ Printing with Melanie Matheu of Prellis Biologics Podcast About Subscribe Cantos Organ Printing with Melanie Matheu of Prellis Biologics Near Frontier Organ Printing with Melanie Matheu of Prellis Biologics Mar 16 2022 | 00:38:29 Your browser does not support the audio tag. 1x 00:00 / 00:38:29 Subscribe Share Apple Podcasts Spotify Overcast RSS Feed Share Link Embed " class="input-embed" /> Episode 5 • March 16, 2022 • 00:38:29 Apple Podcasts Spotify RSS More Show Notes We talk to Prellis Biologics founder Melanie Matheu about bioprinting organs with Prellis' holographic laser technology
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Hype vs. Reality: Why AI Isn't Ready to Make Medicines Yet | TechSurge: Deep Tech VC Podcast Podcast Newsletter TechSurge Summit Summit Overview Past Summits Silicon Valley TechSurge India TechSurge Contact Sign Up TechSurge Pod LIVE: Navigating the AI Intelligence Revolution #SFTechWeek RSVP JUST RELEASED Plausible Tomorrows: What's Ahead in the Age of AI Listen Now Podcast Hype vs. Reality: Why AI Isn't Ready to Make Medicines Yet Hype vs. Reality: Why AI Isn't Ready to Make Medicines Yet March 13, 2025 ABOUT THE EPISODE Many in venture capital and biopharma are anointing … details why, despite significant breakthroughs like AlphaFold and recent Nobel Prize win for computational protein design, fully AI-generated medicines still present challenges. He also discusses why we urgently need more effective medicines and details Prellis’ unique system which combines laser printed human organoids and an externalized human immune system with AI, enabling the discovery of fully human antibodies. If you enjoy this episode, please subscribe and leave us a … protein structures https://deepmind.google/alphafold Read about the 2024 Nobel Prize in Chemistry https://www.nobelprize.org/prizes/chemistry/2024/press-release/ Chapters: 00:00 The Reality of AI in Drug Discovery 03:05 The Need for Better Medicines 06:05 Evolution of Pharmaceutical Therapies 08:55 Challenges in Protein Drug Discovery 12:13 AI's Role in Protein Design 14:46 Limitations of AI in Drug Development 17:58 Understanding Protein Structures 20:54 The Future o … ittle bit and what, what. What we can and can't do with AI, the 2024 Nobel Prize in Chemistry went to the creators of AlphaFold at Google DeepMind, which is a model that uses machine learning to accurately predict a protein's 3D structure. The award was also given to researcher David Baker, who I know you know, for quote, Computational protein design, unquote. On the surface, of course, this sounds like AI designed or discovered proteins, whole cloth, that can creat … be true? Is that a true statement? Mike Nohaile: Yeah. So go back to the Nobel Prize. It was given for two things. One half was given for what's called the protein folding problem. That's given a particular sequence, what does it fold to? And that's a real breakthrough and it works pretty well. Now. The statistics are a little bit
Interview: Dr. Melanie Matheu, Co-founder of Prellis Biologics - 3DHeals Blog All Blogs Guides Expert’s Corner Influencer Interviews Events Courses Directory Podcast More FAQ Career Networking ? Live Facebook Group Meetup Media Store About Pitch3D Login Register Blog Events Courses Directory Podcast More All Blogs Guides Expert’s Corner Influencer Interviews FAQ Career Networking Media Store About Pitch3D ? Live Facebook Group Meetup Home Blog Influencer Interviews Interview: Dr. Melanie Matheu, Co-founder of Prellis Biologics Interview: Dr. Melanie Matheu, Co-founder of Prellis Bi … r career? Melanie: When I left academia, I had just been awarded a transitional grant, I left a fully funded position and a bright academic future to start over in biotech and learn something new. Jenny: What do you enjoy in your spare time? What are you passionate about outside of your work/3d printing? Melanie: I love long distance running. I’m also a very visual person so I still work on making art occasionally. Jenny: What is your favorite quote? Why? Melanie: When a dist
| BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzheimer's disease
#bio2022 #immunology #drugdiscovery #antibodydiscovery #immunooncology #immunogenicity | Prellis Biologics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
Prellis biologics partners with Eli Lilly to advance next-generation human antibody therapeutics Home Categories Ingredients Analysis Manufacturing Finance Company News Regulatory Drug Delivery Research & Development Sustainability Pharma 5.0 Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Manufacturing Chemist Home Research & Development Prellis biologics partners with Eli Lilly to advance next-generation human antibody therapeutics Pharma 5.0 Prellis biologics partners with Eli Lilly to advance next-generation human
Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Mu … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Prellis Biologics News: Updates & Press Releases Technology Portfolio Partnering News & Media About Us Careers Contacts News & Media Press Releases · September 23, 2025 Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics Visit Site All Press Releases News Press Releases · August 10, 2022 Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development Visit Site Press Releases · Dec
Prellis Biologics - SOSV Skip to content Governance in the Age of AI with Author & Investor Eric Ries on June 11 – San Francisco Locations Deep Tech 100 Portfolio News Events Matchups Team Jobs About Invest Copyright All Rights Reserved © 2026 SOSV Investments LLC. All SOSV registered trademarks are owned by SOSV Investments LLC Prellis Biologics Therapeutic drug development company, created via bioprinted lymph node organoids GET CONNECTED prellisbio.com Company details Prellis is leveraging their unique approach to tissue engineering to support the first use of synthetic human tiss … respectively, in the jurisdiction where located; and The International Monetary Fund, the International Bank for Reconstruction and Development, the Inter-American Development Bank, the Asian Development Bank, the African Development Bank, the United Nations, and their agencies, affiliates and pension plans, and any other similar international organizations, their agencies, affiliates and pension plans. No Offer, Solicitation, Advice, or Recommendation Except to the extent ex … Locations Our Portfolio Our Team Legal FAQ Press & Media Brand Guidelines Apply Application FAQ Apply Invest Invest in our Funds Invest in our Companies Participate Jobs at our Companies Our Events Join Talent network Get Email Updates SOSV Consortium Copyright All Rights Reserved © 2026 SOSV Investments LLC. All SOSV registered trademarks are owned by SOSV Investments LLC Privacy Statement Terms of Use Cookie Policy Disclaimer Communication Policy Code of Conduct Press … nt Service Provider Other We don’t spam. Our Privacy Statement and Terms of Use apply. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies or visit "Cookie Settings" to provide a controlled consent. Cookie Policy Cookie Settings Accept All Manage consent Close Cookie Preferences This website uses cookies to improve your experience while you
Prellis Biologics: Antibody Discovery with AI & Immune Diversity Technology Portfolio Partnering News & Media About Us Careers Contacts Bio AI: Harnessing human diversity and AI to build next-generation medicines At Prellis we integrate human biology with machine learning to discover the next generation of therapeutics. Our bioprinted lymph node organoid (LNO™) platform recaptures the complex biology of the human immune system and allows us to mine the vast diversity of the human antibody repertoire in vitro. Key Benefits Hits Hard & High Value Targets Higher hit rates on tough tar
Prellis | Celesta Capital granted update happens via the Termly Consent Mode template inside GTM. Do not add an update listener to this head. ========================================================= --> × United States of America Aaland Islands Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Saint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territo
Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration With Lilly To Advance Human Antibody Therapeutics Get more Drug Discovery insight with our FREE newsletter sign me up Log In or Subscribe Bioinformatics Regulatory Target Research Innovation Preclinical Entrepreneurship Watch Now Drug Discovery Online Live News | September 23, 2025 Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration With Lilly To Advance Human Antibody Therapeutics Collaboration combines Prellis' first-of-a-kind Biological AI – a rapid organoid and AI pl
Mike Nohaile, PhD - Juvena Therapeutics Team Back to Careers Mike Nohaile, PhD Mike Nohaile, PhD, is Chief Executive Officer at Prellis Biologics and former Senior Vice President of Strategy, Commercialization & Innovation at Amgen Inc. Dr. Nohaile joined Amgen as Vice President of Strategy in December 2012. Prior to Amgen, he served as the Head and General Manager of the Molecular Diagnostics Business Unit at Novartis. He served Novartis as the Head of Corporate Strategy and Head of Pharmaceutical Strategy. Mike began his career at McKinsey & Company, as partner in the New Jersey offi
SEC FORM D The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Intentional misstatements or omissions of fact constitute federal criminal violations. See 18 U.S.C. 1001. FORM D Notice of Exempt Offering of Securities OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00 1. Issuer's Identity CIK (Filer ID Number) Previ … ces Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services Oil & Gas Other Energy Health Care Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate C … ot Applicable 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9) Section 3(c)(2) Section 3(c)(10) Section 3(c)(3) Section 3(c)(11) Section 3(c)(4) Section 3(c)(12) Section 3(c)(5) Section 3(c)(13) Section 3(c)(6) Section 3(c)(14) Sec … more than one year? Yes X No 9. Type(s) of Securities Offered (select all that apply) X Equity Pooled Investment Fund Interests Debt Tenant-in-Common Securities Option, Warrant or Other Right to Acquire Another Security Mineral Property Securities Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe) 10. Business Combination Transaction Is this offering being made in connection with a business combination transaction, su … tate/Province/Country ZIP/Postal Code State(s) of Solicitation (select all that apply) Check “All States” or check individual States All States Foreign/non-US 13. Offering and Sales Amounts Total Offering Amount $ 19,252,758 USD or Indefinite Total Amount Sold $ 19,252,758 USD Total Remaining to be Sold $ 0 USD or Indefinite Clarification of Resp
Prellis Biologics, Inc. announced today the close of a $35M C round and Mike Nohaile, PhD joining the team as CEO. Founder Melanie Matheu, PhD will assume the role of CTO and continue to lead… | Prellis Biologics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at an
Dr. Melanie Matheu Health Horizons Speaker - Melanie Matheu Home About Speakers Board Agenda Venues Getting here Acommodations Partners Contact Dr. Melanie Matheu CEO, Founder at Prellis Biologics, Inc. About Dr. Matheu founded Prellis Biologics in October 2016 with a design for an optical based printing system on paper and a vision to create fully vascularized human tissues and organs for transplantation. During her academic career, Dr. Matheu authored numerous peer-reviewed publications and a book chapter detailing methods and approaches for high-resolution imaging in tissues. Melanie was in
VIB Training & Conferences - Melanie Matheu Skip to main content VIB Training & Conferences Conferences account Training account Log in Home Events About About the program Speakers archive Trainer community The user group initiative News Sponsorships FAQ Home Events About About the program Speakers archive Trainer community The user group initiative News Sponsorships FAQ Conferences account Training account Log in Melanie Matheu Melanie Matheu CEO, Founder at Prellis Biologics, Inc., US Visit Matheu's page Dr. Matheu founded Prellis Biologics in October 2016 with a design for an&n
Instagram Instagram Log In Sign Up Close Never miss a post from ucischoolofmedicine Sign up for Instagram to stay in the loop. Sign up Log in Tags ucimedalum ucischoolofmedicine and ucimedalum More options ucischoolofmedicine 32w Alumni Spotlight: Melanie Matheu, PhD '09, Co-founder and CSO of Lyric Bio, Inc. @melanie_matheu_phd is a self-described “research scientist turned inventor and entrepreneur.” The @ucirvine alumna founded Prellis Biologics, based on her novel system for printing human tissue, as well as the spinoff company, LYRIC BIO, which is manufacturing complex therapeutics.
Melanie Matheu | VIB Conferences Skip to main content Asset 2 Conferences User account menu Log in Main navigation Home Event archive Speakers archive About News archive Support us FAQ 0 0 items CHECKOUT Apply Breadcrumb Home > Melanie Matheu Melanie Matheu CEO, Founder at Prellis Biologics, Inc., US More information Visit Matheu's page Biography Dr. Matheu founded Prellis Biologics in October 2016 with a design for an optical based printing system on paper and a vision to create fully vascularized human tissues and organs for transplantation. During her academic career, Dr. Matheu author
How a pandemic pivoted Prellis from laser-printed organs to in vitro immune systems - SOSV Skip to content Governance in the Age of AI with Author & Investor Eric Ries on June 11 – San Francisco Locations Deep Tech 100 Portfolio News Events Matchups Team Jobs About Invest Copyright All Rights Reserved © 2026 SOSV Investments LLC. All SOSV registered trademarks are owned by SOSV Investments LLC Melanie Matheu, PhD. Founder and CEO, Prellis Biologics Sosv founders Prellis Biologics How a pandemic pivoted Prellis from laser-printed organs to in vitro immune systems In December 2021 Prel … uld be able to print them.” Soon after this “aha” moment, Melanie was awarded a grant from the JDRF (Juvenile Diabetes Research Foundation), which meant she could start her own laboratory at a university. It was her ticket to a tenured professorship—a young Ph.D.’s dream come true. Within 24 hours of the JDRF news, a startup contacted Melanie offering her a job as director of immunology. Despite the guarantee of stable income and prestige as a professor, she wanted … o see what she could accomplish in the private sector. She turned down the JDRF grant. Within months the startup failed. But, she says, she was wiser for it. She had witnessed how interpersonal dysfunction among business leaders and investors could affect clinical trials. “I learned so much, so quickly, about the kind of company I didn’t want to run,” says Melanie, stressing that the CEO was great. Others on the executive team, not so much. The idea of tissu … Locations Our Portfolio Our Team Legal FAQ Press & Media Brand Guidelines Apply Application FAQ Apply Invest Invest in our Funds Invest in our Companies Participate Jobs at our Companies Our Events Join Talent network Get Email Updates SOSV Consortium Copyright All Rights Reserved © 2026 SOSV Investments LLC. All SOSV registered trademarks are owned by SOSV Investments LLC Privacy Statement Terms of Use Cookie Policy Disclaimer Communication Policy Code of Conduct Press … nt Service Provider Other We don’t spam. Our Privacy Statement and Terms of Use apply. We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies or visit "Cookie Settings" to provide a controlled consent. Cookie Poli
Prellis Biologics | The Org Platform Enrich Pricing Log in Sign up Prellis Biologics 0 followers Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXIS™, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Industries Biotechnology Headquarters San Francisco, United States Employees 11-50 Links Org chart Teams Offices Positions ( 47 ) Unverified Org chart Mike Nohaile Chief Executive Officer 38 Mike Nohai
Prellis Biologics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 17 Apr 2026 Prellis Biologics, Inc. Holding Company | 2016 | California, United States | 10-50 | www.prellisbio.com Holding Company | 2016 | California, United States | 10-50 | www.prellisbio.com Last update 17 Apr 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Basic Info Introduction Prellis Biologics is a company that specializes in creating human tissues for drug testing and produc … Capital, with participation from Elad Gil, Anthropic & Menlo Ventures Anthology Fund, McKesson Ventures, Avichal Garg/Electric Capital, Moxxie Ventures, Carbon Silicon Ventures, and leaders in AI and life sciences – Othman Laraki (CEO Color Health), Fidji Simo (CEO Instacart, Co-founder Metrodora Institute, OpenAI Board), Mike Nohaile (CEO Prellis Biologics, previously Amgen & Novartis Executive), Kristen Fortney (CEO BioAge), Eric Morgen (COO BioAge), Qasar Younis (CEO Appli … n), Linus Upson (Verily), and Jeffrey Low (Life sciences investor). "At Lux, we fund businesses that turn science fiction into fact. Bluenote is enabling exactly that type of breakthrough innovation—leveraging cutting edge AI to radically reduce the overhead and manual workflows to bring pharmaceutical products into the hands of patients sooner," said Deena Shakir, General Partner at Lux Capital. "The team represents inimitable industry expertise and technical sophistication, … ets, including industry-specific edge cases, and indexes them to support unique application requirements. Bluenote finds that there is no one-size-fits-all model, and instead, combines the best models from Anthropic, OpenAI, Google, and its own fine-tuned models based on proprietary datasets. With new models regularly entering the market, Bluenote continuously evaluates and updates model configurations to ensure that customers are among the first to benefit from the latest ad … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Les Miranda - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Les Miranda Chief Scientific Officer at Prellis Biologics, Inc Les Miranda 's Executive Work History Current Chief Scientific Officer , Chief Scientific Officer Equilar on 07/04/2025 Prellis Biologics, Inc Past To view Les Miranda's complete executive work
Les Miranda - CSO at Prellis Biologics | The Org Platform Enrich Pricing Log in Sign up Prellis Biologics Les Miranda Unverified Les Miranda CSO Contact No bio yet Location Los Angeles, United States Org chart View org chart 1 View manager View position Bhushan Mahadik Director of Research Randall Lowe Senior Director, Chemistry Robin Green Scientific Director Of Platforms BW Bryan Wu Scientific Director Katharina Dueker Principal Scientist CH Clarence Hale Vice President, Biology Teams View all teams This person is not in any teams Offices View all offices This person is not in any offices
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
About Prellis Biologics: Pioneering Antibody Therapeutics Technology Portfolio Partnering News & Media About Us Careers Contacts Bio AI: Harnessing human diversity and AI to build next-generation medicines Integrating human biology with machine learning We aim to revolutionize drug discovery by harnessing the power of the human immune system with tightly-integrated machine learning to develop next-generation antibody therapeutics with unparalleled speed, precision, and safety. We are committed to empowering our pharmaceutical partners with access to the most promising fully human antibody
Prellis Biologics Announces Collaboration with Sanofi - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases Al … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Prellis Biologics Announces Collaboration with Sanofi March 22, 2022 | 2 min read Twitter LinkedIn Facebook Email Print Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. … n bioprinting technology to recreate and engineer human tissues in vitro. A key application is Prellis’ Ex ternalized I mmune S ystem, EXIS, which through the creation of lymph node organoids (LNOs) precisely reproduces the human immune response in vitro. With EXIS, Prellis is able to exploit fully-human immune responses for a variety of applications, including antibody discovery, immunogenicity screening, and T-cell epitope discovery, amongst others. Prellis further leverage … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Thera … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb January 13, 2022 | 2 min read Twitter LinkedIn Facebook Email Print Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug disco … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics September 24, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Collaboration combines Prellis' first-of-a-kind Biological AI – a rapid organoid and AI platform … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Lyric Bio, Inc. Closes $6.6 Million Seed Financing To Revolutionize Donor-Derived Therapeutics - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Lyric Bio, Inc. Closes $6.6 Million Seed Financing To Revolutionize Donor-Derived Therapeutics December 3, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Targeting up to 100x improvement in efficiency to enable 10x more affordable IVIg SAN CARLOS, Calif.--(BUSINESS WIRE)-- Lyric Bio, Inc. , (Lyri … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Human Tissue Engineering Company Prellis Biologics Raises $8.7 Million Series A Round; Announces First Animal Transplant of Its 3D-Printed Tissue - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Man … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Human Tissue Engineering Company Prellis Biologics Raises $8.7 Million Series A Round; Announces First Animal Transplant of Its 3D-Printed Tissue July 30, 2019 | 7 min read Twitter LinkedIn Facebook Email Print Prellis Biologics today announced that Khosla Ventures has led an $8.7 Series A investment in the … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Prellis Biologics, Inc. Announces Vascular Tissue Blanks™, a Series of Ready to Use, Pre-Vascularized Tissue Scaffolds for Complex 3D Cell and Tissue Cultures and Transplantation - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Sea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Prellis Biologics, Inc. Announces Vascular Tissue Blanks™, a Series of Ready to Use, Pre-Vascularized Tissue Scaffolds for Complex 3D Cell and Tissue Cultures and Transplantation December 12, 2018 | 5 min read Twitter LinkedIn Facebook Email Print Tissue engineering company Prellis Biologics launched the fir … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Accelerating Human Tissue Engineering Research: Prellis Biologics Launches TissueWorkshop™ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Ther … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Accelerating Human Tissue Engineering Research: Prellis Biologics Launches TissueWorkshop™ December 10, 2019 | 5 min read Twitter LinkedIn Facebook Email Print Prellis Biologics, Inc. has developed an intuitive web-based interface tailored for biologists and tissue engineers that can be learned in minute SAN … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
CELLINK and Prellis Biologics Inc. sign partnership to commercialize high-resolution holographic bioprinting technology for micro-printing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactur … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business CELLINK and Prellis Biologics Inc. sign partnership to commercialize high-resolution holographic bioprinting technology for micro-printing December 6, 2018 | 3 min read Twitter LinkedIn Facebook Email Print The partners will utilize their IP, expertise, and know-how to offer the first system … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Prellis Biologics Achieves Unprecedented Speed and Resolution in 3D Printing of Human Tissue With Capillaries - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Prellis Biologics Achieves Unprecedented Speed and Resolution in 3D Printing of Human Tissue With Capillaries June 20, 2018 | 5 min read Twitter LinkedIn Facebook Email Print Breakthrough solves a major hurdle in organ and tissue engineering, essential to the goal of eliminating organ transplant waiting list … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Prellis Biologics, Inc. Generates 300 Human Antibodies That Bind the SARS-CoV2 Virus; Pursues Development of a Treatment and Preventative Therapy for COVID-19 Infection - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News D … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Prellis Biologics, Inc. Generates 300 Human Antibodies That Bind the SARS-CoV2 Virus; Pursues Development of a Treatment and Preventative Therapy for COVID-19 Infection May 19, 2020 | 3 min read Twitter LinkedIn Facebook Email Print Prellis Biologics, Inc. announced that it has generated 300 human IgG antibo … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Sh … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development August 10, 2022 | 5 min read Twitter LinkedIn Facebook Email Print Prellis Biologics, Inc (Prellis Bio), a biotherapeutics c … d members: Lei Meng, Senior Therapeutics Analyst of Avidity Partners, and Nobel Prize winner James Rothman, PhD the Sterling Professor of Cell Biology at Yale University. “The multi-billion-dollar antibody therapeutics market is held back by slow discovery. Until now, data on human immune response to guide development of effective drugs or vaccines has only been available through large, expensive clinical trials,” said Michael Marks, Prellis Bio Board Chairman and Founding Ma … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin